Immune system via lipid nanoparticle-mediated antigen delivery (LNP-mediated antigen delivery)

Immune system via lipid nanoparticle (LNP)-mediated antigen delivery is a therapeutic modality rather than a single molecular target. This approach utilizes engineered LNPs—typically composed of ionizable lipids, phospholipids, cholesterol, and PEG-lipids—to encapsulate and protect genetic material or protein antigens for targeted delivery to the immune system (Hou et al., 2021). The primary biological objective is to transport the payload into antigen-presenting cells (APCs), such as dendritic cells, where the antigen can be expressed and presented to T-cells and B-cells to elicit a robust adaptive immune response (Pardi et al., 2018). This platform gained global prominence with the development of mRNA vaccines for COVID-19, demonstrating high efficacy in preventing infectious diseases by mimicking natural viral infection pathways without using live virus (Schoenmaker et al., 2021). Beyond infectious diseases, LNP-mediated delivery is a cornerstone of modern cancer immunotherapy, where it is used to deliver tumor-associated antigens to stimulate the patient's immune system to recognize and destroy malignant cells. The versatility of the LNP platform allows for rapid adaptation to new pathogens or tumor mutations, making it a critical tool in precision medicine and pandemic preparedness.

Other names

mRNA-LNP vaccine platformLipid nanoparticle delivery systemLNP-encapsulated antigen deliveryNanoparticle-mediated immunotherapy

Lipid nanoparticles (LNPs) encapsulate antigenic material, such as mRNA, to protect it from extracellular degradation and facilitate its delivery into the cytoplasm of host cells, particularly professional antigen-presenting cells (APCs). Following endocytosis and endosomal escape, the mRNA is translated into protein antigens which are then processed and presented on MHC class I and II molecules, triggering both cellular (T-cell) and humoral (B-cell) immune responses (Hou et al., 2021; Pardi et al., 2018).